Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study

Emanuela Mundo, Laura Bianchi, Laura Bellodi

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Obsessive-compulsive disorder (OCD) has been successfully treated with proserotonergic agents for some years. Clomipramine was the first drug used, but several clinical trials have been conducted more recently to assess the antiobsessional efficacy of selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to compare the antiobsessional efficacy of three SSRIs, fluvoxamine, paroxetine, and citalopram. Thirty obsessive-compulsive patients without comorbid axis I diagnoses except for tic disorder as assessed by DSM-III-R criteria gave informed consent and were recruited consecutively; they underwent a 10-week randomized treatment with fluvoxamine, paroxetine, or citalopram. Ratings were performed under blind conditions every 2 weeks from baseline to the end of the study and by the Yale-Brown Obsessive-Compulsive Scale, the National Institute of Mental Health-Obsessive-Compulsive Scale, the Clinical Global Impressions Scale, and the Hamilton Rating Scale for Depression. Quantitative and qualitative analyses of the antiobsessional efficacy of the three drugs were completed with analysis of variance with repeated measures and survival analysis. The results showed no significant differences between the three treatments. The preliminary conclusions drawn from this study concern the interchangeable antiobsessional effects of different SSRIs, although further studies of 'cross-response' to these drugs are needed.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume17
Issue number4
DOIs
Publication statusPublished - Aug 1997

Fingerprint

Fluvoxamine
Single-Blind Method
Paroxetine
Citalopram
Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Tic Disorders
Pharmaceutical Preparations
National Institute of Mental Health (U.S.)
Clomipramine
Survival Analysis
Informed Consent
Diagnostic and Statistical Manual of Mental Disorders
Analysis of Variance
Therapeutics
Clinical Trials
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder : A single-blind study. / Mundo, Emanuela; Bianchi, Laura; Bellodi, Laura.

In: Journal of Clinical Psychopharmacology, Vol. 17, No. 4, 08.1997, p. 267-271.

Research output: Contribution to journalArticle

@article{b073b16095a64308b7abb4896cfdb639,
title = "Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study",
abstract = "Obsessive-compulsive disorder (OCD) has been successfully treated with proserotonergic agents for some years. Clomipramine was the first drug used, but several clinical trials have been conducted more recently to assess the antiobsessional efficacy of selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to compare the antiobsessional efficacy of three SSRIs, fluvoxamine, paroxetine, and citalopram. Thirty obsessive-compulsive patients without comorbid axis I diagnoses except for tic disorder as assessed by DSM-III-R criteria gave informed consent and were recruited consecutively; they underwent a 10-week randomized treatment with fluvoxamine, paroxetine, or citalopram. Ratings were performed under blind conditions every 2 weeks from baseline to the end of the study and by the Yale-Brown Obsessive-Compulsive Scale, the National Institute of Mental Health-Obsessive-Compulsive Scale, the Clinical Global Impressions Scale, and the Hamilton Rating Scale for Depression. Quantitative and qualitative analyses of the antiobsessional efficacy of the three drugs were completed with analysis of variance with repeated measures and survival analysis. The results showed no significant differences between the three treatments. The preliminary conclusions drawn from this study concern the interchangeable antiobsessional effects of different SSRIs, although further studies of 'cross-response' to these drugs are needed.",
author = "Emanuela Mundo and Laura Bianchi and Laura Bellodi",
year = "1997",
month = "8",
doi = "10.1097/00004714-199708000-00005",
language = "English",
volume = "17",
pages = "267--271",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder

T2 - A single-blind study

AU - Mundo, Emanuela

AU - Bianchi, Laura

AU - Bellodi, Laura

PY - 1997/8

Y1 - 1997/8

N2 - Obsessive-compulsive disorder (OCD) has been successfully treated with proserotonergic agents for some years. Clomipramine was the first drug used, but several clinical trials have been conducted more recently to assess the antiobsessional efficacy of selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to compare the antiobsessional efficacy of three SSRIs, fluvoxamine, paroxetine, and citalopram. Thirty obsessive-compulsive patients without comorbid axis I diagnoses except for tic disorder as assessed by DSM-III-R criteria gave informed consent and were recruited consecutively; they underwent a 10-week randomized treatment with fluvoxamine, paroxetine, or citalopram. Ratings were performed under blind conditions every 2 weeks from baseline to the end of the study and by the Yale-Brown Obsessive-Compulsive Scale, the National Institute of Mental Health-Obsessive-Compulsive Scale, the Clinical Global Impressions Scale, and the Hamilton Rating Scale for Depression. Quantitative and qualitative analyses of the antiobsessional efficacy of the three drugs were completed with analysis of variance with repeated measures and survival analysis. The results showed no significant differences between the three treatments. The preliminary conclusions drawn from this study concern the interchangeable antiobsessional effects of different SSRIs, although further studies of 'cross-response' to these drugs are needed.

AB - Obsessive-compulsive disorder (OCD) has been successfully treated with proserotonergic agents for some years. Clomipramine was the first drug used, but several clinical trials have been conducted more recently to assess the antiobsessional efficacy of selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to compare the antiobsessional efficacy of three SSRIs, fluvoxamine, paroxetine, and citalopram. Thirty obsessive-compulsive patients without comorbid axis I diagnoses except for tic disorder as assessed by DSM-III-R criteria gave informed consent and were recruited consecutively; they underwent a 10-week randomized treatment with fluvoxamine, paroxetine, or citalopram. Ratings were performed under blind conditions every 2 weeks from baseline to the end of the study and by the Yale-Brown Obsessive-Compulsive Scale, the National Institute of Mental Health-Obsessive-Compulsive Scale, the Clinical Global Impressions Scale, and the Hamilton Rating Scale for Depression. Quantitative and qualitative analyses of the antiobsessional efficacy of the three drugs were completed with analysis of variance with repeated measures and survival analysis. The results showed no significant differences between the three treatments. The preliminary conclusions drawn from this study concern the interchangeable antiobsessional effects of different SSRIs, although further studies of 'cross-response' to these drugs are needed.

UR - http://www.scopus.com/inward/record.url?scp=0030843141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030843141&partnerID=8YFLogxK

U2 - 10.1097/00004714-199708000-00005

DO - 10.1097/00004714-199708000-00005

M3 - Article

C2 - 9241005

AN - SCOPUS:0030843141

VL - 17

SP - 267

EP - 271

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -